Argos Therapeutics Inc (NASDAQ:ARGS)
Argos Therapeutics Inc (NASDAQ:ARGS) shares gained over 5% in spite of establishing a new 52-week low before the end of today’s trading. It was a stange trading day for Argos Therapeutics Inc (NASDAQ:ARGS). Shares closed on Tuesday at $0.30 then gapped up to open at $0.41 before hitting their interday high of $0.47 – then ARGS shares plummeted to a new 52-week low of $0.29 before closing at $0.31.
ARGS shares spiked early on news of immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection – published in the Journal of AIDS Research and Human Retroviruses. The study achieved its primary endpoint, with all six patients demonstrating a positive immune response. The favorable results of this study provide support for Argos Therapeutics Inc (NASDAQ:ARGS) ongoing HIV eradication study in which AGS-004 is being administered in combination with vorinostat, a latency-reversing drug. This study is being conducted at the University of North Carolina, with planned enrollment of up to 12 patients and with initial data expected in early 2018.
Argos Therapeutics Inc (NASDAQ:ARGS) shares have been trading under $1 since March of this year. Shareholders have lost over 93% YTD, and over 95% for the year. At least two investment firms lowered the stock’s rating in 2017. Shareholders have never seen a profit. In 2012 the loss per share was (-$0.61) and that loss expanded annually until 2016 when the loss shrank to come in at (-$1.66). Sales have had a downward trajectory. In 2012 sales were posted at $7 million but by 2016 the sales figure was just $0.90 million.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $ARGS and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.